Meningococcal Conjugate Vaccine Market - Industry Analysis, Market Size, Share, Trends, Growth and Forecast 2022 - 2027

Report Code: HCR 89641 Report Format: PDF + Excel

Meningococcal Conjugate Vaccine Market Overview

Meningococcal Conjugate Vaccine Market size is estimated to reach $4.32 billion by 2027, growing at a CAGR of 9.8% during the forecast period 2022-2027. Meningococcal is also recognized as IMD (= Invasive Meningococcal Disease). It can be elucidated as a grievous contagion which is disseminated by bacilli “Neisseria meningitidis.” The disease is caused mainly due to three types of bacteria B, C, and Y. Similarly, MenACWY vaccines cure infections caused due to Serogroups (A, W, C, and Y). Serogroup B has a different vaccine MenB to cure Serogroup B Meningococcal which frequently leads to two main sicknesses meningitis and blood circulation contagion. A person inflicted with MM (=Meningococcal Meningitis) experiences headache, fever, and inelastic neck ascribing to the contamination and protuberance in tissues acting as a shield to the brain and spinal cord. Whereas, in bloodstream infection, NM enters the blood and devastates arteries and veins. Undue flows of hard cash into exploration and development by governments around the world post-COVID-19 are set to drive the growth of the Meningococcal Conjugate vaccine Industry for the period 2022-2027.

Report Coverage:

The report: “Meningococcal Conjugate Vaccine Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Meningococcal Conjugate Vaccine Market.

By Serogroup: MenACWY, MenB, MenW, MenC, MenA, and many more.
By End User: Infants, Toddlers, Adolescents, and Adults.
By Type: MCV4 (=Meningococcal Conjugate), MPSV4 (= Meningococcal Polysaccharide Vaccine), Combined vaccines.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (the Middle East and Africa).

Key Takeaways:

  • Geographically, North America into research and development accounted for the highest revenue share in 2021. However, Asia Pacific is poised to dominate the market over the period 2022-2027 owing to the ascension in the overall population of the Asian nations.
  • The proliferation in the activities of research and development, and across the board accessibility of vaccines are driving the market. However, the harmful effects of various vaccines related to the disease are said to reduce the growth of the Meningococcal Conjugate Vaccine Market.
  • Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Meningococcal Conjugate Vaccine Market report.

    Meningococcal Conjugate Vaccine Market- Geography (%) for 2021.

For More Details on This Report - Request for Sample

Meningococcal Conjugate Vaccine Market Segment Analysis - By Serogroup

The Meningococcal Conjugate Vaccine Market based on the Serogroup can be further segmented into MenACWY, MenB, MenW, MenC, and many more. The MenACWY segment held the largest share owing to the factors such as the majority of the meningococcal ailments around the world are caused only by the serogroups A, C, W, and Y. Infants and children are more prone towards meningococcal and MenACWY widely used to treat infants and children up to 10 years. By aiming for the said serogroups, it helps in saving close to 350 million people worldwide.

Moreover, the MenACWY segment is estimated to be the fastest-growing segment with a CAGR of 10.4% over the period 2022-2027. This growth is owing to a higher ability to make antibodies that targets the bacteria or virus leading to the malady, increasing cases of meningococcal inflicted by bacteria which belongs to subgroups (A, C, W, and Y), across the board presence of MenACWY vaccine.

Meningococcal Conjugate Vaccine Market Segment Analysis - By End User

The Meningococcal Conjugate Vaccine Market based on End User can be further segmented into Infants, Toddlers, Adolescents, and Adults. The Infant segment held the largest share in 2021 owing to the factors such as high rates of immune disorders in infants and children, most of the time meningococcal gravitates towards infants because of their lower weight problems during birth. Another big factor for its prevalence is the constant embracing and kissing of infants by their parents as meningococcal is a communicable disease.

The old-age segment is estimated to be the fastest-growing with a CAGR of 10.6% over the forecast period 2022-2027. This growth is owing to ascension in the geriatric population and an upsurging prevalence of meningococcal in elderly people. The old-age population percentage was around 9.1% in 2019 and is estimated to touch the 16-17% mark in the upcoming future.

Meningococcal Conjugate Vaccine Market Segment Analysis - By Geography

The Meningococcal Conjugate Vaccine Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 35% of the overall market in 2021. The growth in this segment is owing to the factors such as the rising prevalence of meningococcal in infants and old age people, elevating geriatric population in North American countries such as Canada and the US, state-of-the-art healthcare infrastructure, and across the board presence of vaccines required to fight such maladies, highly cognizant population.

However, Asia-Pacific is estimated to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to the rising population gravitating such communicable diseases at a large scale, elevating investments in research and development of new procedures and vaccines by governments and private players, refining healthcare infrastructure in various developing Asian nations such as India, Indonesia, and China.

Meningococcal Conjugate Vaccine Market Drivers

Refining healthcare infrastructure and elevating research and development financings Projected to Drive Market Growth

After the Covid outbreak, there has been an innumerable swell in various transmissible maladies around the globe. Therefore, the healthcare sector is on the top of the governments' priority list. Developing countries are assembling colossal packages for research and development and augmenting their general healthcare spending. Recently, the Indian government has amplified healthcare spending by 137%. Even US total healthcare spending is assessed to reach the $6 trillion mark by the year 2028-2029. Therefore, ascribing to heightening flows of hard cash drug and vaccine development activities are increasing around the globe which is estimated to boost Meningococcal Conjugate Vaccine Market.

Budding old age population is Expected to Boost Product Demand

The total population of earth in 2021 is around 7.9 billion people. But out of these 7.9 billion, a big chunk of people is aging above 65 and is expected to enlarge up to 1-2 billion in the coming future. As of 2021 around 19% of total Europe’s population falls under the category of geriatric population. Similarly, in Asian nations like India and China old age population is shooting up. As a result, bacteria like “Neisseria meningitidis” are predominating which is considered as a prominent factor to boost the demand of the meningococcal conjugate Vaccine market.

Meningococcal Conjugate Vaccine Market Challenges

Harmful effects of vaccines and delay in approvals are Anticipated to Hamper Market Growth

Vaccines are not 100% safe and deliver copious side effects post usage. Similarly, meningococcal conjugate vaccines such as MenACWY, MenB constitute several health coercions in many cases. Almost entirely loss of palate, tenderness, headache, strain in sleeping is customary in patients administered with respective vaccines. On top of that, international health bodies such as WHO and individual governments of countries take forever in giving approvals to vaccines that can mutilate the development of the meningococcal conjugate vaccine market.

Meningococcal Conjugate Vaccine Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in this market. Meningococcal Conjugate Vaccine top 10 companies include:

  1. Sanofi
  2. GlaxoSmithKline plc
  3. Pfizer
  4. Merck & Company
  5. Serum Institute of India Ltd.
  6. Novartis AG
  7. Walvax Biotechnology Co., Ltd.
  8. Bio-Med Pvt Ltd.
  9. Hualan Biological Engineering, Inc.
  10. Oswaldo Cruz Foundation

Partnerships/Recent Developments:

  • October 27, 2021, vaccine against meningitis B a sickness triggered by the bacteria belonging to serogroup B is now accessible in the United Arab Emirates. Earlier, it was obtainable only in a few overseas countries like UK and US. Earlier, the parents had to take their children to a different location, for them to be vaccinated. Bexsero is also available at Harley Street Medical Centre in Abu Dhabi, among others.
  • April 24, 2020, the Sanofi-made conjugate vaccine “MenQuadfi” has got the nod from FDA (=Food and Drug Administration). The vaccine is specially made for treating children inflicted with meningococcal and aging two years or older than that. MenQuadfi was designed to elicit and demonstrate a high immune response across all four serogroups for multiple ages and was well tolerated. MenQuadfi is intended to protect an expanded age group. Licensure marks MenQuadfi as the only U.S. FDA-approved quadrivalent meningococcal vaccine indicated for persons 2 through 56 years of age and older.

Relevant Reports:

Report Code: HCR 67449

Report Code: HCR 84690

For more Lifesciences and Healthcare Market reports, please click here

1. Meningococcal Conjugate Vaccine Market Overview
    1.1 Definitions and Scope
2. Meningococcal Conjugate Vaccine Market- Executive Summary
3. Meningococcal Conjugate Vaccine Market– Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Meningococcal Conjugate Vaccine Market– Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Meningococcal Conjugate Vaccine Market– Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Meningococcal Conjugate Vaccine Market- Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Meningococcal Conjugate Vaccine Market– By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Meningococcal Conjugate Vaccine Market- By serogroup (Market Size –$Million/$Billion) 
    8.1 MenACWY
    8.2 MenB
    8.3 MenW
    8.4 MenC
    8.5 MenA, and many more
9. Meningococcal Conjugate Vaccine Market- By End User (Market Size –$Million/$Billion) 
    9.1 Infants
    9.2 Toddlers
    9.3 Adolescents
    9.4 Adults
10. Meningococcal Conjugate Vaccine Market– Type (Market Size –$Million/$Billion) 
    10.1 MCV4 (=Meningococcal Conjugate)
    10.2 MPSV4 (= Meningococcal Polysaccharide Vaccine)
    10.3 Combined vaccines
11. Meningococcal Conjugate Vaccine Market- By Geography (Market Size -$Million/Billion)
    11.1 North America
        11.1.1 U.S
        11.1.2 Canada
        11.1.3 Mexico
    11.2 South America
        11.2.1 Brazil
        11.2.2 Argentina
        11.2.3 Chile
        11.2.4 Colombia
        11.2.5 Rest of South America
    11.3 Europe
        11.3.1 Germany
        11.3.2 France
        11.3.3 UK
        11.3.4 Italy
        11.3.5 Spain
        11.3.6 Russia
        11.3.7 Rest of Europe
    11.4 Asia-Pacific
        11.4.1 China
        11.4.2 Japan
        11.4.3 South Korea
        11.4.4 India
        11.4.5 Australia & New Zealand
        11.4.6 Rest of Asia-Pacific
    11.5 Rest of World
        11.5.1 Middle East
        11.5.2 Africa
12. Meningococcal Conjugate Vaccine Market- Market Entropy
    12.1 New product launches
    12.2 M&A's, collaborations, JVs, and partnerships
13. Meningococcal Conjugate Vaccine Market– Industry Competition Landscape (Premium)
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key Companies
        13.1.3 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Meningococcal Conjugate Vaccine Market– Key Company List by Country Premium (Premium)
15. Meningococcal Conjugate Vaccine Market- Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"

LIST OF TABLES

1.Global Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
1.1 Mono Vaccine Market 2019-2024 ($M) - Global Industry Research
1.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
1.2 Combination Vaccine Market 2019-2024 ($M) - Global Industry Research
2.Global Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
2.1 Menactra Market 2019-2024 ($M) - Global Industry Research
2.2 Menveo Market 2019-2024 ($M) - Global Industry Research
2.3 Neisvac-C Market 2019-2024 ($M) - Global Industry Research
2.4 Nimenrix Market 2019-2024 ($M) - Global Industry Research
3.Global Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
3.1 Child Market 2019-2024 ($M) - Global Industry Research
3.2 Preteen Or Teen Market 2019-2024 ($M) - Global Industry Research
3.3 Adult Market 2019-2024 ($M) - Global Industry Research
4.Global Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 (Volume/Units)
4.1 Mono Vaccine Market 2019-2024 (Volume/Units) - Global Industry Research
4.1.1 Key Growth Factor And Opportunity Market 2019-2024 (Volume/Units)
4.2 Combination Vaccine Market 2019-2024 (Volume/Units) - Global Industry Research
5.Global Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 (Volume/Units)
5.1 Menactra Market 2019-2024 (Volume/Units) - Global Industry Research
5.2 Menveo Market 2019-2024 (Volume/Units) - Global Industry Research
5.3 Neisvac-C Market 2019-2024 (Volume/Units) - Global Industry Research
5.4 Nimenrix Market 2019-2024 (Volume/Units) - Global Industry Research
6.Global Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 (Volume/Units)
6.1 Child Market 2019-2024 (Volume/Units) - Global Industry Research
6.2 Preteen Or Teen Market 2019-2024 (Volume/Units) - Global Industry Research
6.3 Adult Market 2019-2024 (Volume/Units) - Global Industry Research
7.North America Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
7.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
7.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
7.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
8.North America Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
8.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
8.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
8.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
8.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
9.North America Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
9.1 Child Market 2019-2024 ($M) - Regional Industry Research
9.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
9.3 Adult Market 2019-2024 ($M) - Regional Industry Research
10.South America Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
10.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
10.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
10.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
11.South America Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
11.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
11.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
11.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
11.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
12.South America Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
12.1 Child Market 2019-2024 ($M) - Regional Industry Research
12.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
12.3 Adult Market 2019-2024 ($M) - Regional Industry Research
13.Europe Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
13.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
13.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
13.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
14.Europe Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
14.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
14.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
14.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
14.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
15.Europe Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
15.1 Child Market 2019-2024 ($M) - Regional Industry Research
15.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
15.3 Adult Market 2019-2024 ($M) - Regional Industry Research
16.APAC Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
16.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
16.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
16.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
17.APAC Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
17.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
17.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
17.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
17.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
18.APAC Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
18.1 Child Market 2019-2024 ($M) - Regional Industry Research
18.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
18.3 Adult Market 2019-2024 ($M) - Regional Industry Research
19.MENA Global Meningococcal Conjugate Vaccine Market, By Composition Market 2019-2024 ($M)
19.1 Mono Vaccine Market 2019-2024 ($M) - Regional Industry Research
19.1.1 Key Growth Factor And Opportunity Market 2019-2024 ($M)
19.2 Combination Vaccine Market 2019-2024 ($M) - Regional Industry Research
20.MENA Global Meningococcal Conjugate Vaccine Market, By Brand Market 2019-2024 ($M)
20.1 Menactra Market 2019-2024 ($M) - Regional Industry Research
20.2 Menveo Market 2019-2024 ($M) - Regional Industry Research
20.3 Neisvac-C Market 2019-2024 ($M) - Regional Industry Research
20.4 Nimenrix Market 2019-2024 ($M) - Regional Industry Research
21.MENA Global Meningococcal Conjugate Vaccine Market, By End User Market 2019-2024 ($M)
21.1 Child Market 2019-2024 ($M) - Regional Industry Research
21.2 Preteen Or Teen Market 2019-2024 ($M) - Regional Industry Research
21.3 Adult Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
2.Canada Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
3.Mexico Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
4.Brazil Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
5.Argentina Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
6.Peru Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
7.Colombia Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
8.Chile Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
9.Rest of South America Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
10.UK Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
11.Germany Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
12.France Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
13.Italy Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
14.Spain Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
15.Rest of Europe Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
16.China Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
17.India Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
18.Japan Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
19.South Korea Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
20.South Africa Meningococcal Conjugate Vaccine Market Revenue, 2019-2024 ($M)
21.North America Meningococcal Conjugate Vaccine By Application
22.South America Meningococcal Conjugate Vaccine By Application
23.Europe Meningococcal Conjugate Vaccine By Application
24.APAC Meningococcal Conjugate Vaccine By Application
25.MENA Meningococcal Conjugate Vaccine By Application
26.Sanofi Pasteur, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Pfizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Hualan Biological Engineering Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Jn International Medical Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Baxter International Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Serum Institute Of Pvt Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Biomed Pvt Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Novartis Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)